Phathom Pharmaceuticals, Inc. announced the appointment of Molly Henderson to the position of Chief Financial and Business Officer. Ms. Henderson will join the Company effective April 5, 2022. Ms. Henderson most recently served as Chief Financial Officer of UroGen Pharma (Nasdaq: URGN), a commercial-stage biopharmaceutical company focused on building novel treatments for specialty cancers and urologic disease.

She brings over two decades of global finance expertise and has extensive experience in financial planning and analysis, investor relations, and capital raising.